Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Harvard Business School
Express Scripts
Chinese Patent Office
Queensland Health

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,863,742

« Back to Dashboard

Summary for Patent: 4,863,742

Title: Controlled absorption pharmaceutical composition
Abstract:A controlled absorption verapamil containing pellet formulation for oral adminstration comprises a core of a powder mixture containing verapamil or a pharmaceutically acceptable salt thereof and an organic acid and a polymeric material, said core comprising layers of said powder mixture and said polymeric material superimposed one upon the other and said polymeric material being present in an amount effective to ensure that all of said powder mixture is coated into said core and a multi-layer membrane surrounding said core, the number of layers in said membrane and the ratio of the various polymers comprising the membrane being effective to permit release of the verapamil from the pellet at a rate allowing controlled absorption thereof over a 24 hour period following oral administration, said rate being measured in vivo and having a Tmax between 6 and 16 hours.
Inventor(s): Panoz; Donald E. (Tuckerstown, BM), Geoghegan; Edward J. (Westmeath, IE)
Assignee: Elan Corporation PLC (Athlone, IE)
Application Number:07/064,765
Patent Claim Types:
see list of patent claims
Formulation; Dosage form; Composition; Process; Use;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,863,742

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Ireland1661/86Jun 20, 1986

International Patent Family for Patent: 4,863,742

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria72975► Subscribe
Australia599385► Subscribe
Australia7452887► Subscribe
Germany3776982► Subscribe
European Patent Office0250267► Subscribe
Spain2039440► Subscribe
Greece3003978► Subscribe
Ireland58401► Subscribe
Japan2637981► Subscribe
JapanS635021► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Argus Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus